AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2259918 — intervention group
Group type: COMPARATOR
Intervention: NOAC II without rhGM‐CSF
Number of subjects: 31
Study 385094 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 63
Study 385094 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium in combination with tryptophan (Optimax)
Number of subjects: 63
Study 385094 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 63
Study 385094 — intervention group
Group type: COMPARATOR
Intervention: Tryptophan alone
Number of subjects: 63
Study 31988481 — intervention group
Group type: EXPERIMENTAL
Intervention: The Daily Mile intervention
Number of subjects: 2256
Study 31988481 — intervention group
Group type: EXPERIMENTAL
Intervention: The Daily Mile intervention (specifically in girls)
Number of subjects: 2256
Study 31988481 — intervention group
Group type: EXPERIMENTAL
Intervention: The Daily Mile intervention (economic analysis)
Number of subjects: 2256
Study 31988481 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual school health and wellbeing activities)
Number of subjects: 2256
Study 30975953 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave glazing
Number of subjects: 4
Study 30975953 — intervention group
Group type: COMPARATOR
Intervention: Conventional oven glazing
Number of subjects: 4
Study 28256307 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 80/4.5 μg (160/9 μg) BID
Number of subjects: 279
Study 28256307 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 80/2.25 μg (160/4.5 μg) BID
Number of subjects: 279
Study 28256307 — intervention group
Group type: COMPARATOR
Intervention: Budesonide pMDI 80 μg (160 μg) BID
Number of subjects: 279
Study 25815738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexfin device
Number of subjects: 13
Study 25815738 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance cardiography
Number of subjects: 13
Study 23722456 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 consecutive daily intratympanic injections of 4 mg/ml dexamethasone
Number of subjects: 56
Study 23722456 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 consecutive weekly injections of 4 mg/ml dexamethasone
Number of subjects: 56
Study 21193260 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel™
Number of subjects: 267
Study 21193260 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-Supreme™
Number of subjects: 267
Study 21193260 — intervention group
Group type: COMPARATOR
Intervention: BVM
Number of subjects: 267
Study 21193260 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 267
Study 21193260 — intervention group
Group type: COMPARATOR
Intervention: LMA-Unique™
Number of subjects: 267
Study 21193260 — intervention group
Group type: COMPARATOR
Intervention: LMA-ProSeal™
Number of subjects: 267
Study 21193260 — intervention group
Group type: EXPERIMENTAL
Intervention: All SADs
Number of subjects: 267
Study 19273865 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate blood test
Number of subjects: 498
Study 19273865 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting approach
Number of subjects: 498
Study 17542503 — intervention group
Group type: EXPERIMENTAL
Intervention: Load-sharing anterior cervical plate (ACP) system
Number of subjects: 50
Study 17542503 — intervention group
Group type: COMPARATOR
Intervention: Stress-shielding anterior cervical plate (ACP) system
Number of subjects: 50
Study 15829494 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) 200 mg/m²/day orally for five consecutive days every 4 weeks
Number of subjects: 132
Study 15829494 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (TMZ) + Cisplatin (CDDP) 200 mg/m² daily on days 1-5 and 75 mg/m² of CDDP on day 1
Number of subjects: 132
Study 11928794 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10234749 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer advisor intervention for unpartnered elders recovering from MI
Number of subjects: 0
Study 7852219 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 0
Study 7852219 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2586199 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoplex 10 mg
Number of subjects: 0
Study 2586199 — intervention group
Group type: COMPARATOR
Intervention: Nolvadex 10 mg
Number of subjects: 0
Study 1102399 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrate of clotting factors
Number of subjects: 30
Study 1102399 — intervention group
Group type: COMPARATOR
Intervention: Fresh frozen plasma
Number of subjects: 30
Study 31314107 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy (n = 120)
Number of subjects: 247
Study 31314107 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (n = 127)
Number of subjects: 247
Study 28189417 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram-based FSH starting dose (based on multiple biomarkers)
Number of subjects: 191
Study 28189417 — intervention group
Group type: COMPARATOR
Intervention: Age-based FSH starting dose (150 IU if ≤35 years, 225 IU if >35 years)
Number of subjects: 191
Study 25384017 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression CAREPATH intervention (nurses managing depression at routine home visits with weekly symptom assessment, medication management, care coordination, education, and goal setting)
Number of subjects: 306
Study 25384017 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression CAREPATH intervention
Number of subjects: 306
Study 25384017 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 306
Study 23211762 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (20 mg L and 2 mg Z)
Number of subjects: 54
Study 23211762 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (10 mg L, 2 mg Z and 10 mg MZ)
Number of subjects: 54
Study 23211762 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (3 mg L, 2 mg Z and 17 mg MZ)
Number of subjects: 54
Study 21560845 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose I-131 treatment (150 microCi/gm, initial mean activity 10.2 mCi)
Number of subjects: 150
Study 21560845 — intervention group
Group type: COMPARATOR
Intervention: Low dose I-131 treatment (100 microCi/gm, initial mean activity 8 mCi)
Number of subjects: 150
Study 21560845 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose I-131 treatment
Number of subjects: 150
Study 21560845 — intervention group
Group type: COMPARATOR
Intervention: Low dose I-131 treatment
Number of subjects: 150
Study 19705423 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary Contraction (VG)
Number of subjects: 30
Study 19705423 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyostimulation superimposed on Voluntary Contraction (EVG)
Number of subjects: 30
Study 19705423 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study 16442367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin
Number of subjects: 4558
Study 16442367 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 4558
Study 15867743 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit training with an electronic monitoring device
Number of subjects: 41
Study 15867743 — intervention group
Group type: COMPARATOR
Intervention: Standard habit training (Control)
Number of subjects: 41
Study 11231429 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/d)
Number of subjects: 200
Study 11231429 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (40 mg/d)
Number of subjects: 200
Study 9476493 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bifonazole (Mycospor Solution) alone (group I)
Number of subjects: 0
Study 9476493 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bifonazole (Mycospor Solution) plus 10% urea ointment (Urepearl) (group II)
Number of subjects: 0
Study 8122478 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 210
Study 8122478 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 20 mg
Number of subjects: 210
Study 3627208 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of oral corticosteroids (methylprednisolone, 32 mg) approximately 12 hours and 2 hours before challenge with contrast material
Number of subjects: 6763
Study 30067931 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month regimen of rifampin
Number of subjects: 6859
Study 30067931 — intervention group
Group type: COMPARATOR
Intervention: 9-month regimen of isoniazid
Number of subjects: 6859
Study 26578422 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine/timolol fixed combination (BTFC)
Number of subjects: 95
Study 26578422 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol
Number of subjects: 95
Study 26049920 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG) combined with cyclosporine A (CsA)
Number of subjects: 0
Study 26049920 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 0
Study 26049920 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe aplastic anemia (SAA) group
Number of subjects: 0
Study 23701339 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with alfentanil (10 μg/kg alfentanil followed by 1 mg/kg propofol, followed by 0.5 mg/kg every 3 minutes as needed)
Number of subjects: 20
Study 23701339 — intervention group
Group type: COMPARATOR
Intervention: Propofol only (1 mg/kg propofol, followed by 0.5 mg/kg every 3 minutes as needed)
Number of subjects: 20
Study 20963671 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-assisted aftercare group treatment
Number of subjects: 168
Study 20963671 — intervention group
Group type: COMPARATOR
Intervention: No additional outpatient psychotherapy (control)
Number of subjects: 168
Study 17846859 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 427
Study 17846859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 427
Study 17846859 — intervention group
Group type: COMPARATOR
Intervention: HRT (oral, transdermal, intranasal)
Number of subjects: 427
Study 17846859 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 427
Study 16876921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal monitoring education programme (1.5 hr duration)
Number of subjects: 55
Study 16876921 — intervention group
Group type: COMPARATOR
Intervention: Alternative education programme (non-fetal-monitoring-related video presentation)
Number of subjects: 55
Study 12801957 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 42
Study 12801957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 12801957 — intervention group
Group type: EXPERIMENTAL
Intervention: Open label infliximab (10 mg/kg)
Number of subjects: 42
Study 12801957 — intervention group
Group type: COMPARATOR
Intervention: Open label placebo
Number of subjects: 42
Study 11199363 — intervention group
Group type: EXPERIMENTAL
Intervention: White wine (300 ml, 8% vol/vol)
Number of subjects: 12
Study 11199363 — intervention group
Group type: COMPARATOR
Intervention: Ethanol solution (8% vol/vol)
Number of subjects: 12
Study 11199363 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 12
Study 11199363 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet swallow (5 ml)
Number of subjects: 12
Study 11199363 — intervention group
Group type: COMPARATOR
Intervention: All beverages (White wine, Ethanol solution, Tap water)
Number of subjects: 12
Study 8636546 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal acid stimulation (0.1 mol/liter hydrochloric acid)
Number of subjects: 32
Study 8636546 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution
Number of subjects: 32
Study 1602194 — intervention group
Group type: EXPERIMENTAL
Intervention: Rees' STA
Number of subjects: 4108
Study 1602194 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 4108
Study 3901244 — intervention group
Group type: EXPERIMENTAL
Intervention: MOCCA chemotherapy regimen (vincristine, methylprednisolone, and 3 alkylating agents)
Number of subjects: 50
Study 3901244 — intervention group
Group type: EXPERIMENTAL
Intervention: MOCCA courses bimonthly after 12 months
Number of subjects: 50
Study 3901244 — intervention group
Group type: COMPARATOR
Intervention: No further chemotherapy after 12 months
Number of subjects: 50
Study 28604508 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy alone
Number of subjects: 142
Study 28604508 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy with arthroplasty
Number of subjects: 142
Study 28604508 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy with fusion by plate fixation
Number of subjects: 142
Study 27148992 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splints (OS)
Number of subjects: 30
Study 27148992 — intervention group
Group type: EXPERIMENTAL
Intervention: Relining of old denture (RD)
Number of subjects: 30
Study 27148992 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study 23918212 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate treatment
Number of subjects: 0
Study 23451445 — intervention group
Group type: EXPERIMENTAL
Intervention: hylan G-F 20
Number of subjects: 32
Study 23451445 — intervention group
Group type: COMPARATOR
Intervention: hyaluronic acid (HA)
Number of subjects: 32
Study 20484826 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-site Bachmann's bundle pacing (BBp)
Number of subjects: 40
Study 20484826 — intervention group
Group type: COMPARATOR
Intervention: Coronary sinus pacing (CSp)
Number of subjects: 40
Study 20484826 — intervention group
Group type: COMPARATOR
Intervention: Multisite atrial pacing (MSAp)
Number of subjects: 40
Study 18283201 — intervention group
Group type: EXPERIMENTAL
Intervention: CONSORT checklist modifications for nonpharmacologic trials
Number of subjects: 33
Study 16003672 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-water therapy (40 degrees C)
Number of subjects: 24
Study 16003672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water therapy (13 degrees C)
Number of subjects: 24
Study 16003672 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast therapy
Number of subjects: 24
Study 16003672 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 24
Study 12527252 — intervention group
Group type: EXPERIMENTAL
Intervention: One-legged hopping in patients with ACL reconstruction
Number of subjects: 7
Study 12527252 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 7
Study 10655859 — intervention group
Group type: EXPERIMENTAL
Intervention: Opaque foam dressing
Number of subjects: 37
Study 10655859 — intervention group
Group type: COMPARATOR
Intervention: Transparent film dressing
Number of subjects: 37
Study 10655859 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study 8717309 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy (prednisolone 20‐60 mg/day orally, or pulse therapy)
Number of subjects: 51
Study 1908630 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release nifedipine (20 mg at 10 P.M. or 2 doses of 20 mg at 10 P.M. and 6 A.M.)
Number of subjects: 15
Study 1908630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1908630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine therapy
Number of subjects: 15
Study 6815153 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple contact procedure (postcard and two telephone call reminders)
Number of subjects: 125
Study 6815153 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive procedure (selecting among four gifts contingent on seeking care)
Number of subjects: 125
Study 6815153 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive + problem-solve procedure (combination of incentive and problem-solve techniques)
Number of subjects: 125
Study 6815153 — intervention group
Group type: COMPARATOR
Intervention: Control procedure (parents given a dentist's name)
Number of subjects: 125
Study 6815153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive strategies (multiple contact, incentive, and incentive + problem-solve)
Number of subjects: 125
Study 6815153 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple contact technique
Number of subjects: 125
Study 31721914 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic in the diet (0.01 g kg‐1)
Number of subjects: 0
Study 31721914 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic in the water (0.002 g L‐1)
Number of subjects: 0
Study 31721914 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial probiotic (Saccharomyces cerevisiae) in the diet (1 g Kg‐1)
Number of subjects: 0
Study 31721914 — intervention group
Group type: COMPARATOR
Intervention: Control (water and diet without additives)
Number of subjects: 0
Study 31721914 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic in the water and yeast in the diet (0.002 g L‐1 and 1 g Kg‐1)
Number of subjects: 0
Study 31721914 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast in the diet (1 g Kg‐1)
Number of subjects: 0
Study 27827824 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/sirolimus (Tac/Sir)
Number of subjects: 211
Study 27827824 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus/methotrexate (Tac/Mtx)
Number of subjects: 211
Study 25808099 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery (SCS)
Number of subjects: 135
Study 25808099 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT)
Number of subjects: 135
Study 24028201 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength exercise group
Number of subjects: 207
Study 24028201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling group
Number of subjects: 207
Study 24028201 — intervention group
Group type: COMPARATOR
Intervention: Control group (doing as usual)
Number of subjects: 207
Study 21834707 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP)
Number of subjects: 60
Study 21834707 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% carbamide peroxide (CP)
Number of subjects: 60
Study 21834707 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% carbamide peroxide (CP)
Number of subjects: 60
Study 21834707 — intervention group
Group type: EXPERIMENTAL
Intervention: All bleaching systems tested
Number of subjects: 60
Study 19108951 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT (Acceptance and Commitment Therapy)
Number of subjects: 32
Study 19108951 — intervention group
Group type: COMPARATOR
Intervention: MDT (Multidisciplinary Treatment)
Number of subjects: 32
Study 16574123 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral intravenous cannulas re‐sited only when complications occurred
Number of subjects: 206
Study 16574123 — intervention group
Group type: COMPARATOR
Intervention: Peripheral intravenous cannulas re‐sited every 3 days
Number of subjects: 206
Study 15475527 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) infusion during rhythmic handgrip (RHG) exercise
Number of subjects: 25
Study 15475527 — intervention group
Group type: COMPARATOR
Intervention: Saline control during rhythmic handgrip (RHG) exercise
Number of subjects: 25
Study 15475527 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive exercise in HF patients
Number of subjects: 25
Study 15475527 — intervention group
Group type: COMPARATOR
Intervention: Passive exercise in healthy controls
Number of subjects: 25
Study 16305056 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone plus sulphonylurea
Number of subjects: 177
Study 16305056 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone plus metformin
Number of subjects: 177
Study 10022494 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual instruction cues
Number of subjects: 0
Study 10022494 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory trigger stimulus
Number of subjects: 0
Study 10022494 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement-related responses
Number of subjects: 0
Study 10022494 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction cue and sustained activity during delay
Number of subjects: 0
Study 7479391 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate specific antigen (PSA) levels
Number of subjects: 502
Study 7479391 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate specific antigen density (PSAD)
Number of subjects: 502
Study 2404805 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone 1.25 mg twice weekly (group I)
Number of subjects: 12
Study 2404805 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone 2.5 mg twice weekly (group II)
Number of subjects: 12
Study 2404805 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of gestrinone
Number of subjects: 12
Study 6991101 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 79
Study 6991101 — intervention group
Group type: COMPARATOR
Intervention: Fluoxymesterone
Number of subjects: 79
Study 30570303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance-based Body Project treatment (BPT)
Number of subjects: 84
Study 30570303 — intervention group
Group type: COMPARATOR
Intervention: Supportive mindfulness treatment
Number of subjects: 84
Study 28265678 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg daily for 4 weeks
Number of subjects: 50
Study 28265678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25948780 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus coagulans GBI-30, 6086 (BC30)
Number of subjects: 36
Study 25948780 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 36
Study 25022156 — intervention group
Group type: EXPERIMENTAL
Intervention: UL+RE (N = 10)
Number of subjects: 21
Study 25022156 — intervention group
Group type: COMPARATOR
Intervention: UL (N = 11)
Number of subjects: 21
Study 22972300 — intervention group
Group type: EXPERIMENTAL
Intervention: Political mobilization messages delivered via Facebook
Number of subjects: 61000000
Study 22972300 — intervention group
Group type: EXPERIMENTAL
Intervention: Social transmission effects from users who received messages
Number of subjects: 61000000